Effects and mechanism of siomycin A on the growth and apoptosis of MiaPaCa-2 cancer cells

BIN WANG1, WEI WANG1, HAO-YI MENG1, JING CHEN2 and LI-JIE YUAN1

1Hebei Key Laboratory for Chronic Diseases, Tangshan Key Laboratory for Preclinical and Basic Research on Chronic Diseases, School of Basic Medical Sciences; 2College of Life Science, North China University of Science and Technology, Tangshan, Hebei 063210, P.R. China

Received August 29, 2018; Accepted June 6, 2019

DOI: 10.3892/ol.2019.10633

Abstract. Siomycin A is a type of thiopeptide antibiotic that is isolated from the fermentation products of an endophytic actinomycin, which is derived from the medicinal plant Acanthopanax senticosus. The present study investigated whether siomycin A has antitumor effects in vitro on a variety of cell lines. A Cell Counting Kit-8 assay was performed to detect the effects of siomycin A on cell viability; morphological changes in the MiaPaCa-2 cell line were analyzed using an inverted phase contrast microscope. A Transwell migration assay was applied to detect cell migration ability. The cytoskeleton was observed by laser confocal microscopy, and apoptosis was detected using flow cytometry. A western blot assay was used to detect the expression of matrix metalloproteinase (MMP)-2, MMP-9 and α-tubulin. The results revealed that siomycin A inhibited the proliferation of human tumor cell lines of different origins. As the concentration of siomycin A increased, the cell density decreased gradually and cells exhibited a morphological change from spindle to spherical shape. Furthermore, 24 h after administration, the cell migration ability was inhibited. The cytoskeleton complexity and morphological changes were increased after administration of siomycin A. The percentage of apoptotic cells was significantly increased and the expression levels of MMP-2, MMP-9 and α-tubulin were downregulated by siomycin A. Therefore, siomycin A was determined to effectively inhibit the proliferative ability of a variety of human tumor cell lines. Siomycin A was also determined to affect the cytoskeleton of tumor cells by downregulating the expression of α-tubulin protein.

Introduction

Malignant tumors are a major disease, and pose serious threat to human life and health (1). There are currently >100 known types of malignancy that affect humans (2). In recent years, the overall incidence of malignant tumors has exhibited an upward trend (3). Malignant tumors are the main cause of death, and the mortality rate of patients with malignant tumors is slightly lower compared with that due to heart disease, particularly in the majority of developed countries (4). In China, malignant tumors are the second major cause of mortalities in cities and rural areas (5). Patients who live in developed countries, including Europe and the United States have a five‑year standardized survival rate of 60-70%; however, a survival rate of 30.9% has been reported for China, while that of rural areas is half of that in cities (6). Therefore, it is imperative to identify more effective novel anti-tumor drugs.

The fermentation products of Actinomycetes are an important natural source of anti-tumor drugs and have various chemical structures (7). The majority of them have innovative mechanisms and are easy to mass produce. Siomycin A is a type of thiopeptide antibiotic that is isolated from the fermentation products of an endophytic actinomycin, which is derived from the medicinal plant Acanthopanax senticosus (8). At present, the inhibitory effect of siomycin A on tumor cells has only been demonstrated in a limited number of cell lines and the mechanism of siomycin A in tumor cells is not yet clear (9,10). In the present study, a number of human tumor cell lines were selected to investigate whether siomycin A has antitumor effects in vitro.

Materials and methods

Cell lines, media and chemical compounds. Siomycin A was isolated and identified by Liu et al (11). In the present study, siomycin A at a final concentration of 0, 0.625, 1.25, 2.5, 5 or 10 µmol/l; medium containing 0.5% dimethyl sulfoxide or 0 µmol/l siomycin A served as the controls. The K562
human leukemia cell line, MCF7 human breast cancer cell line and MiaPaCa-2 human pancreatic cancer cell line were purchased from the Cell Center, Peking Union Medical College (Beijing, China). Dulbecco's Modified Eagle's medium (DMEM) was obtained from Corning Inc., and fetal bovine serum (FBS) was purchased from Bovogen Biologicals Pty Ltd. Triton X-100, dimethyl sulfoxide and DAPI were acquired from Sigma-Aldrich (Merck KGaA). Transwell chambers were obtained from BD Pharmingen (BD Biosciences). α-tubulin and β-actin antibodies were purchased from Antibody Revolution company, and matrix metallopeptinase (MMP)-2 and MMP-9 antibodies were acquired from Affinity Biosciences. Peroxidase-labeled antibody to mouse immunoglobulin G (IgG) was purchased from KPL Inc.

**Cell culture.** The K562 cell line was cultured with RPMI-1640 medium (Invitrogen; Thermo Fisher Scientific, Inc.). The cell lines were maintained with 10% FBS and 1% penicillin-streptomycin (Gibco; Thermo Fisher Scientific, Inc.). The K562 cell line was cultured with RPMI-1640 medium (Corning Inc.). Both types of media were supplemented with 10% FBS and 1% penicillin-streptomycin (Gibco; Thermo Fisher Scientific, Inc.). The cell lines were maintained at 37°C in 5% CO2.

**Viability assay.** The viability assay was performed according to the manufacturer's protocols of the CCK-8 kit (Beijing Zoman Biotechnology Co., Ltd.). Cell suspensions (100 µl; 3x10^4 cells/ml) with 10% FBS medium were added to a 96-well plate and the plate was incubated for 6 h at 37°C. Subsequently, 10 µl CCK-8 reagent was added to each well and then the cells were incubated for 2 h at 37°C. The optical density at a wavelength of 450 nm was measured using an ELx800 microplate reader (BioTek Instruments, Inc.). Similar assays were performed after incubation for 24, 48 and 72 h and the experiments were performed in triplicate. Cell viability was expressed as the half maximum inhibitory concentration (IC50) value and data were analyzed with the software Microsoft Office Excel 2010 (Microsoft Corporation).

**Morphological changes.** Briefly, 3x10^5 MiaPaCa-2 cells were incubated at 37°C for 24 h with or without siomycin A at concentrations of 0.625, 1.25, 2.5, 5 and 10 µmol/l in 60-mm diameter tissue culture dishes. Subsequently, the medium was discarded and the cells were washed once with PBS. The morphological changes of the apoptotic cells were observed using an inverted phase contrast microscope (CX31; Olympus Corporation, Tokyo, Japan) at x100 magnification.

**Transwell migration assay.** The assays were performed using a Corning Transwell permeable support system with 8.0 µm pore size. A total of 1x10^4 cells were suspended in serum-free DMEM and were placed in the upper chamber of a Transwell plate. Siomycin A at a final concentration of 0.625, 1.25, 2.5, 5 or 10 µmol/l was added to the lower chamber, which DMEM containing 10% FBS. After incubation for 20 h at 37°C, the cells on the upper surface of the filter were removed using a cotton swab, 2 drops of the Rapid Gram Stain (Zhuhai Baso Biotechnology Co., Ltd.) solution were added to the cells that had migrated to the membrane at room temperature for 30 sec and were washed with water. Migration was observed in six randomly selected fields with a light Olympus CX31 microscope. Cells in each image were counted with the ImageJ 1.52a software (National Institutes of Health, USA).

**Cytoskeleton assay.** MiaPaCa-2 cells were inoculated into laser confocal culture dishes at a density of 6x10^3 cells/well and cultured for 24 h. The cells were treated and incubated with various concentrations of siomycin A. After rinsing three times with Hank’s Balanced Salt Solution (HBSS; Beijing Solarbio Science & Technology Co., Ltd.), cells were incubated with 200 µl murine anti-human α-tubulin (1:200; cat. no. ARH4207; Antibody Revolution Inc.) overnight at 4°C in a wet box. Cells were then washed with HBSS three times for 10 min and incubated with 200 µl goat anti-mouse IgG-fluorescein isothiocyanate (FITC) (1:50; cat. no. 074-1506; SeraCare Life Sciences) at room temperature for 30 min in the dark. Cells were washed three times with HBSS for 10 min and incubated with 10 µl DAPI nuclear stain for 5 min at room temperature in the dark. The unbound nuclear stain was washed with HBSS. The dishes were placed under a laser scanning confocal microscope (TCS SP8 STED 3X; Leica Microsystems GmbH; magnification, x600) and scanned at 488 nm (excitation) and 543 nm (detection) for the analysis of green fluorescence. A total of five fields were randomly scanned for each group to obtain fluorescence images and analyzed with Image J 1.6.0.24 software (National Institutes of Health), in order to observe the cytoskeleton of the cells.

**Apoptosis detection by flow cytometry.** Cells that have reached ~80% confluence were detached using 0.25% trypsin without EDTA (Beijing Solarbio Science & Technology Co., Ltd.) at 37°C. The control and treated cells were stained using an Annexin V-FITC/propidium iodide (PI) apoptosis detection kit (BD Biosciences), according to the manufacturer's protocols. After double staining with FITC-conjugated Annexin V and PI, the cells were analyzed by flow cytometry (Leica TCS SP8 STED; Leica Microsystems GmbH). The experiments were performed in triplicate (SPSS 19.0; IBM Corp.).

**Western blot analysis.** All of the treated cell groups were harvested and lysed with cell lysis buffer (cat. no. BB-3201-1; BestBio) for western blot analysis. The protein concentrations were determined by a NanoDrop 2000 spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc.). Proteins (5-10 µg, 10-30 µg) were separated using 8-10% SDS-PAGE and transferred to polyvinylidene difluoride membranes (EMD Millipore). The membranes were blocked in TBST containing 5% non-fat skim milk at room temperature for 2 h. After washing with TBST in triplicate, the membranes were incubated with primary antibodies against MMP-2 (1:500; cat. no. AF0577; Affinity Biosciences), MMP-9 (1:1,500; cat. no. AF5228; Affinity Biosciences), α-tubulin (1:5,000; cat. no. ARH4207; Antibody Revolution Co., Ltd.) and β-actin (1:5,000; cat. no. ARH4419; Antibody Revolution Co., Ltd.) for 2 h at 37°C. Subsequently, the membranes were washed and incubated with an appropriate horseradish peroxidase-link linked secondary antibody (1:5,000; cat. no. 074-1506; KPL Inc.) for 20 min at 37°C. Bands were developed with an enhanced chemiluminescence blot detection system (UVP BioSpectrum Imaging System; Analytik Jena AG). The data were analyzed via densitometry using ImageJ 1.52a software (National Institutes of Health).
Statistical analysis. Statistical comparisons were performed with SPSS 19.0 software (IBM Corp.). The results are presented as the mean ± standard deviation. One-way analysis of variance was used for multiple comparisons followed by a Student-Newman-Keuls post hoc test. P<0.05 was considered to indicate a statistically significant difference.

Results

Siomycin A inhibits the proliferation of human tumor cell lines. Siomycin A inhibited the proliferation of a variety of human tumor cell lines. Cell viability was reduced with increases in drug concentration, which demonstrates a dose-dependent effect. Furthermore, cell viability markedly decreased as the drug treatment period increased, which demonstrates a time-dependent association (Fig. 1). Among the three cell lines, the IC50 of the human leukemia K562 cells was the lowest at 6.25±3.60 µmol/l at 24 h, while that for the human pancreatic cancer MiaPaCa-2 cells was 6.38±5.73 µmol/l. However, the IC50 of the human pancreatic cancer MiaPaCa-2 cells at 48 and 72 h were the lowest of the three cell lines, which were 0.76±0.51 and 0.54±0.02 µmol/l, respectively (Table I). Therefore, MiaPaCa-2 cells were selected for the subsequent experiments.

Siomycin A changes the morphology and inhibits the migration of MiaPaCa-2 cells. The MiaPaCa-2 cells were treated with different concentrations of siomycin A for 24 h and then changes in cell morphology were observed under an inverted phase contrast microscope. The cells in the solvent, and 0, 0.625 and 1.25 µmol/l groups had a high cell density and a better growth state. Furthermore, there was no significant difference in the cell morphology of these groups. When the concentration of siomycin A was 2.5 µmol/l, the cell density began to decrease and the cell size was reduced, but the cells remained spindle-shaped. In the 5 and 10 µmol/l groups, a large number of cells had shrunk into a spherical shape and exhibited many small bright spots; the cell density was notably reduced (Fig. 2A). Subsequently, the effect of siomycin A on the migration of the MiaPaCa-2 cells was detected. After treatment with various concentrations of siomycin A for 24 h, the number of cells penetrating into the Transwell chamber was reduced with increases in drug concentration (Fig. 2B). Compared with the 0 µmol/l group, cell mobility was significantly reduced in the 2.5, 5 and 10 µmol/l groups (P<0.05).

Effects of siomycin A on the cytoskeleton of MiaPaCa-2 cells. The MiaPaCa-2 cells were treated with various concentrations of siomycin A for 24 h, and then changes in the cytoskeletons were detected using a laser confocal microscope. In the 0 µmol/l group, the distribution of green filamentous microtubules in the cytoplasm of the MiaPaCa-2 cells was regular and they were arranged radially from the nucleus to the surroundings. With the increase in drug concentration, the cell began to shrink, the number of microtubules reduced or had disappeared, the fluorescence distribution was clustered and partially contracted to the nucleus, and the fluorescence intensity was notably enhanced. There were slight changes in the nuclei of the cells in the 2.5, 5 and 10 µmol/l groups (Fig. 3). The images were processed according to the method of a previous study (12). The distribution of the microtubule skeleton was analyzed with ImageJ software fractal box counting tool. The software automatically maps the absissa log (box size) and ordinate log (count) values, and the resulting slope is the fractal dimension D. The results are presented in Table II. The fractal dimensions of the 2.5, 5 and 10 µmol/l groups were significantly reduced compared with the 0 µmol/l group (P<0.05). The results demonstrated that the complexity of the cytoskeleton was reduced and the morphological differences in the cytoskeleton were increased in the MiaPaCa-2 cells that were treated with siomycin A.

Effects of siomycin A on the apoptosis of MiaPaCa-2 cells. Using Annexin V-FITC/PI double staining, analysis of the apoptosis of the MiaPaCa-2 cells treated with different concentrations of siomycin A demonstrated the potent proapoptotic effect of siomycin A. Compared with the 0 µmol/l group, the percentage of apoptotic cells was significantly increased in the 2.5, 5 and 10 µmol/l groups (P<0.05; Fig. 4).

Effects of siomycin A on the protein levels of MMP-2, MMP-9 and α-tubulin in MiaPaCa-2 cells. In order to investigate the mechanism of siomycin A on inhibiting migration and affecting the cytoskeleton of MiaPaCa-2 cells, the protein levels of MMP-2, MMP-9 and α-tubulin were evaluated. The results of the western blot analysis demonstrated that the expression levels of MMP-2 and MMP-9 protein in the MiaPaCa-2
cells were significantly reduced in the 2.5, 5 and 10 µmol/l groups. The expression of α-tubulin protein was significantly decreased in the 1.25, 2.5, 5 and 10 µmol/l groups compared with the 0 µmol/l group (Fig. 5).
The increasing incidence of malignant tumors necessitates the identification of novel therapeutic compounds. The majority of novel compounds identified originate from microbes (13). Siomycin A is a thiopeptide antibiotic that was isolated from the fermentation product of *Streptomyces sioyaensis* by Nishimura in 1959 (14). Using a high-throughput drug screening system, Radhakrishnan et al. (9) demonstrated that siomycin A specifically inhibits the transcription and expression of Forkhead box family (Fox)M1 without affecting other members of the Forkhead box family. FoxM1 is a transcription factor of the Forkhead family (15) that is overexpressed in a variety of tumor cell types, including liver cancer, pancreatic cancer, breast cancer and lung adenocarcinoma cells (16-21).

A previous study demonstrated that siomycin A effectively reduces the expression of maternal embryonic leucine zipper kinase and inhibits tumor growth in mice (10). Another study found that siomycin A inhibits tumor cell growth and survival by downregulating the expression of BUB1 mitotic checkpoint serine/threonine kinase B protein (22). In addition, siomycin A can inhibit the invasive ability of laryngeal carcinoma HEp-2 cells and reduce the levels of MMP-2 and MMP-9 protein in them (23).

The present study demonstrated that siomycin A has an inhibitory effect on three human tumor cell lines in a time- and dose-dependent manner. Based on the comprehensive evaluation of the IC₅₀, the human pancreatic cancer MiaPaCa-2 cell line was selected as a model to analyze the inhibitory effect of siomycin A on tumor cells and investigate the underlying mechanism.

The density of the human pancreatic cancer MiaPaCa-2 cells treated with different concentrations of siomycin A.

| Concentration (µmol/l) | Cell dimension |
|------------------------|---------------|
| Control                | 1.67±0.03     |
| 0                      | 1.65±0.05     |
| 0.625                  | 1.63±0.11     |
| 1.25                   | 1.67±0.04     |
| 2.5                    | 1.47±0.14 a   |
| 5                      | 1.37±0.17 a   |
| 10                     | 1.31±0.13 a   |

*P<0.05 vs. the 0 µmol/l group.

### Table I. IC₅₀ of three tumor cell lines at different time points.

| Cell line | 24 h (µmol/l) | 48 h (µmol/l) | 72 h (µmol/l) |
|-----------|---------------|---------------|---------------|
| K562      | 6.25±3.60     | 1.18±0.04     | 1.24±0.12     |
| MiaPaCa-2 | 6.38±5.73     | 0.76±0.51     | 0.54±0.02     |
| MCF-7     | 19.61±7.28    | 2.97±0.02     | 1.98±0.03     |

IC₅₀, half maximum inhibitory concentration.

### Figure 3. Effects of siomycin A on the cytoskeleton of MiaPaCa-2 cells. The cells were treated with solvent control, or 0, 0.625, 1.25, 2.5, 5 and 10 µmol/l siomycin A for 24 h. The cytoskeleton changes were observed under a laser confocal microscope. A-G represents treatments with increasing concentrations of siomycin A (control and 0, 0.625, 1.25, 2.5, 5 and 10 µmol/l).
Figure 4. Effects of siomycin A on the apoptosis of MiaPaCa-2 cells. The apoptosis assay was performed with Annexin V-FITC/PI double staining and representative plots of the MiaPaCa-2 cells treated with the indicated dose of siomycin A are shown. The apoptotic ratio was calculated and plotted. *P<0.05 vs. the 0 µmol/l group. FITC, fluorescein isothiocyanate; PI, propidium iodide.

Figure 5. Effects of siomycin A on the protein levels of MMP-2, MMP-9 and α-tubulin in MiaPaCa-2 cells. (A) Detection of MMP-2, MMP-9 and α-tubulin protein expression by western blot. (B) Expression of MMP-2 relative to β-actin protein under different concentrations of siomycin A. (C) Expression of MMP-9 relative to β-actin protein under different concentrations of siomycin A. (D) Expression of α-tubulin relative to β-actin protein under different concentrations of siomycin A. The cells were treated with solvent control, or 0, 0.625, 1.25, 2.5, 5 and 10 µmol/l siomycin A for 24 h. The protein levels were determined using western blot analysis. *P<0.05 vs. the 0 µmol/l group. MMP, matrix metalloproteinase. For each panel, A-G represents treatments with increasing concentrations of siomycin A (control and 0, 0.625, 1.25, 2.5, 5 and 10 µmol/l).
morphological changes of apoptosis. The percentage of apoptotic MiaPaCa-2 cells was significantly increased with increases in drug concentration. When the drug concentration was 10 μmol/l, the percentage of apoptotic cells reached 58.40±3.35% (Fig. 4), which demonstrates a dose-dependent effect. This result is consistent with the results of a previous study, which showed that siomycin A induces apoptosis of human laryngeal carcinoma HEp-2 cells (23).

In order to investigate the effect of siomycin A on the migration of tumor cells, a Transwell migration assay was used to detect changes in cell migration. Compared with the 0 μmol/l group, the number of migrated cells was significantly lower in the 2.5-10 μmol/l groups (P<0.05). The results suggest that siomycin A inhibited the migration of tumor cells; the aforementioned results are consistent with that of Jiang et al (26), who demonstrated that siomycin A inhibits the migration and invasion of human nasopharyngeal carcinoma C666-1 cells. Furthermore, the expression levels of MMP-2 and MMP-9 were detected using western blot analysis. The results demonstrated that the expression levels of MMP-2 and MMP-9 in the 2.5-10 μmol/l groups were significantly lower than in the 0 μmol/l group (P<0.05). Therefore, the mechanism of the inhibitory effect of siomycin A on human pancreatic cancer cell migration may be associated with downregulation of MMP-2 and MMP-9 protein expression. The results are similar to those of Nakano et al (10), who treated polymorphic glioblasts with siomycin A, and demonstrated that the expression levels of MMP-2 and MMP-9 were reduced. Previous studies have shown the association of FoxM1 with MMP-2 and MMP-9 in various types of cancer, including clear cell renal cell carcinoma, glioma cells and papillary thyroid carcinoma, leading to the increased invasiveness and migratory ability of cancer cells causing metastasis. And targeting FoxM1 has been shown to inhibit these cellular properties via MMP-2 and MMP-9 downregulation (27-29).

In conclusion, the present study proposed that siomycin A inhibits the proliferation and migration of cancer cells, and demonstrated that siomycin A also induces cell apoptosis. The inhibitory effects of siomycin A on tumor cells may be associated with downregulation of α-tubulin skeletal protein expression, which affects the cytoskeleton of tumor cells. Experiments of the present study were limited to investigations at the cellular level and these results are not sufficient to elucidate the anti-tumor mechanism of siomycin A. Further animal experiments will be conducted to elucidate the mechanism of siomycin A action, as well as the role of α-tubulin skeletal protein.

Acknowledgements

Not applicable.

Funding

This study was supported by the National Science Foundation of Hebei Province (grant nos. C2014209137 and H2013209040).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors’ contributions

BW, JC and LY designed experiments. BW, WW and HM performed experiments. BW analyzed the data. BW, JC and LY wrote the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.
References

1. Ji-Jun D, Ya-Qiong Y, Nian-Nian Y, Jing Z, Rong-Shou Z and Si-Wei Z: International comparison analysis of China's cancer incidence and mortality. Chin J Frontiers of Med Sci (Electronic Version), 2016 (In Chinese).

2. Hu XQ, Zhou GQ and Wang SX: Application of combined detection of T lymphocyte and DNT cells in early diagnosis of malignant tumor. Labeled Immunoassays Clin Med 23: 139-142, 2016 (In Chinese).

3. Torre LA, Siegel RL, Ward EM and Jemal A: Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomarkers Prev 25: 16-27, 2016.

4. Zaorsky NG, Churilla TM, Egleston BL, Fisher SG, Ridge JA, Horwitz EM and Meyer JE: Causes of death among cancer patients. Ann Oncol 28: 400-407, 2017.

5. Shengshou HU, Runlin GAO, Lisheng LIU, Manlu ZHU, Wen WANG, Yongjun WANG, Huijun LI, Dongfeng GU, Yuejin YANG, et al: Summary of the 2018 report on cardiovascular diseases in China. Chin Circulation J 3: 204, 2019 (In Chinese).

6. Chen W, Zheng R, Zhang S, Zhao P, Zeng H and Zou X: Report of cancer incidence and mortality in China, 2010. Ann Transl Med 2: 61, 2014.

7. Sharma M, Dangi P and Choudhary M: Actinomycetes: Source, identification, and their applications. Int J Curr Microbiol App Sci 3: 801-832, 2014.

8. Li L, Ai-Hua L, Hao R, Ning H, Ru-Xian C and Li-Jie Y: Bioactive secondary metabolite study and strain identification of Planomonospora sp. 12 from Acanthopanax senticosus. Chin J Antibiotics 40: 321-324, 349, 2019.

9. Radakrishnan SK, Bhat UG, Hughes DE, Wang IC, Costa RH and Garrel AL: Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res 66: 9731-9735, 2006.

10. Nakano I, Yoshikawa M, Nakamura Y, Iwata M, Furunuma K, Chiba T, et al: Siomycin A affects the cytoskeleton of tumor cells. Oncogene 23: 2385-2400, 2004.